Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluconazole dosing for chronic vulvovaginal candidiasis
ACTRN12614001258640Phase 4Terminated
- Sponsor
- Royal North Shore Hospital
- Start
- Mar 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of fluconazole in vulvovaginal candidiasis (VVC) (3 arms), sponsored by Royal North Shore Hospital. Primary endpoints: Presence of chronic vulvovaginal candidiasis symptoms at 6 weeks and Presence of chronic vulvovaginal candidiasis symptoms at 12 weeks. Started Mar 2015; status: terminated.
02
Drugs
fluconazole
03
Conditions
vulvovaginal candidiasis (VVC)
Beyond the preview
Go deeper on ACTRN12614001258640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614001258640.